Table 1 Distribution of serological factors and −1C→T polymorphism in the study population.
| Thrombosis (arterial or venous) | Arterial thrombosis | Venous thrombosis | Pregnancy morbidity | |
|---|---|---|---|---|
| Total population, n = 198 | 60 | 32 | 38 | 24 |
| DRVVT, n = 61 | 41 | 21 | 27 | 11 |
| APTT, n = 58 | 36 | 19 | 22 | 10 |
| LAC, n = 63 | 41 | 21 | 27 | 11 |
| aCL IgG, n = 102 | 44 | 21 | 29 | 15 |
| aCL IgM, n = 66 | 32 | 16 | 20 | 12 |
| aCL IgG/IgM, n = 112 | 46 | 22 | 30 | 16 |
| Anti‐β2‐GPI IgG, n = 52 | 32 | 16 | 21 | 12 |
| Anti‐β2‐GPI IgM, n = 28 | 17 | 9 | 10 | 9 |
| Anti‐β2‐GPI IgG/IgM, n = 62 | 36 | 19 | 22 | 14 |
| Antiprothrombin IgG, n = 73 | 31 | 14 | 24 | 10 |
| Antiprothrombin IgM, n = 42 | 21 | 8 | 14 | 6 |
| Antiprothrombin IgG/IgM, n = 95 | 38 | 18 | 27 | 12 |
| Anti‐annexin A5 IgG, n = 53 | 19 | 10 | 14 | 10 |
| Anti‐annexin A5 IgM, n = 27 | 13 | 4 | 9 | 4 |
| Anti‐annexin A5 IgG/IgM, n = 71 | 27 | 12 | 20 | 12 |
| Annexin A5 −1C→T polymorphism, n = 46 | 15 | 10 | 8 | 10 |
aCL, anticardiolipin antibody; APTT, activated partial thromboplastin time; β2‐GPI, β2‐glycoprotein I; DRVVT, dilute Russell's viper venom time; Ig, immunoglobulin; LAC, lupus anticoagulant; RVVT, Russell's viper venom time.
APTT interassay coefficient of variation (CV): 2.0%; aCL CV: 6.9%; anti‐β2‐GPI antibody CV: 11.5%; RVVT CV: 3.2%.